The estimated Net Worth of Punit Dhillon is at least 64.6 千$ dollars as of 1 February 2018. Punit Dhillon owns over 3,000 units of OncoSec Medical Inc stock worth over 64,597$ and over the last 17 years Punit sold ONCS stock worth over 0$.
Punit has made over 9 trades of the OncoSec Medical Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Punit bought 3,000 units of ONCS stock worth 2,640$ on 1 February 2018.
The largest trade Punit's ever made was buying 50,000 units of OncoSec Medical Inc stock on 19 March 2014 worth over 40,000$. On average, Punit trades about 3,346 units every 54 days since 2008. As of 1 February 2018 Punit still owns at least 230,702 units of OncoSec Medical Inc stock.
You can see the complete history of Punit Dhillon stock trades at the bottom of the page.
Punit's mailing address filed with the SEC is C/O ONCOSEC MEDICAL INCORPORATED, 4690 EXECUTIVE DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Over the last 12 years, insiders at OncoSec Medical Inc have traded over 1,474,366$ worth of OncoSec Medical Inc stock and bought 9,275,650 units worth 39,853,210$ . The most active insiders traders include Grand Pharmaceutical & Heal...、Holdings, Inc. Alpha、Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of 51,563$. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth 55$.
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Inc executives and other stock owners filed with the SEC include: